365 results on '"Özcan, Muhit"'
Search Results
2. CHRONOS-4: phase 3 study of copanlisib plus rituximab-based immunochemotherapy in relapsed indolent B-cell lymphoma
3. Phase 3 SELENE study: ibrutinib plus BR/R-CHOP in previously treated patients with follicular or marginal zone lymphoma
4. Cusatuzumab plus azacitidine in newly diagnosed acute myeloid leukaemia ineligible for intensive chemotherapy (CULMINATE): part one of a randomised, phase 2, dose optimisation study
5. Alpha-1-Antitrypsin Experience for Steroid-Resistant Acute Graft-Versus-Host Disease
6. Quality-of-life analysis of pembrolizumab vs brentuximab vedotin for relapsed/refractory classical Hodgkin lymphoma
7. Lenfoplazmasitik Lenfomada Yeni Nesil Dizileme Yöntemiyle Mutasyon İncelemesinin Tanı ve Tedavi Planında Yeri
8. Copanlisib plus rituximab versus placebo plus rituximab in patients with relapsed indolent non-Hodgkin lymphoma (CHRONOS-3): a double-blind, randomised, placebo-controlled, phase 3 trial
9. Efficacy and safety of copanlisib in patients with relapsed or refractory marginal zone lymphoma
10. Biomarkers of response to ibrutinib plus nivolumab in relapsed diffuse large B-cell lymphoma, follicular lymphoma, or Richter's transformation
11. Long-term results of brentuximab vedotin in relapsed and refractory Hodgkin lymphoma: multi-center real-life experience
12. Real-world efficacy and safety of Rituximab, Lenalidomide and İbrutinib combination in patients with Relapsed and/or Refractory Non-Hodgkin Lymphoma
13. Vitamin D Gene Polymophism in Patients with Aseptic Necrosis after Allogeneic Hematopoietic Stem Cell Transplantation
14. P1073: A NEW SCORING SYSTEM TO PREDICT SURVIVAL IN ELDERLY ADVANCED STAGE HODGKIN LYMPHOMA PATIENTS: STUDY BY TURKISH SOCIETY OF HAEMATOLOGY LYMPHOMA ACADEMY WORKING GROUP
15. PB2655: EVALUATION OF THE EFFICACY AND SAFETY IMMUNOSUPPRESSIVE THERAPY IN PATIENTS WITH ACQUIRED FACTOR VIII AND IX INHIBITOR
16. Evaluation of the Efficacy and Safety Immunosuppressive Therapy in Patients with Acquired Factor VIII and IX Inhibitor
17. Pembrolizumab in Relapsed or Refractory Primary Mediastinal Large B-Cell Lymphoma: Final Analysis of KEYNOTE-170
18. Eltrombopag for the Treatment of Poor Graft Function Following Haematopoietic Cell Transplantation: Real-Life Data
19. Are Generic Imatinib Formulations Really as Effective as Originial Imatinib in Chronic Myeloid Leukemia: Real Life Data
20. The Impact of CD34+ Cell and Immunefector Cell Dose on Transplant Outcomes
21. Polatuzumab Vedotin Plus Bendamustine and Rituximab in Relapsed/Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL): Final Results of a Phase Ib/II Randomized Study and Single-Arm Extension (Ext) Study
22. Pembrolizumab and Chemotherapy in Newly-Diagnosed, Early Unfavorable or Advanced Stage Classic Hodgkin Lymphoma: The Phase 2 Keynote-C11 Study
23. Glofitamab in Relapsed/Refractory Diffuse Large B Cell Lymphoma: Real World Data
24. Pooled Safety Analysis from Phase I-III Studies for Patients with Hematological Malignancies Treated with the PI3K Inhibitor Copanlisib
25. Relevance of Additional Immunohistochemical Markers in the Differential Diagnosis of Small B-Cell Lymphomas: A Case-Control Study
26. Ibrutinib plus Bendamustine and Rituximab in Untreated Mantle-Cell Lymphoma
27. Clinical Characteristics and Outcomes of COVID-19 in Turkish Patients with Hematological Malignancies COVID-19 Geçiren Türk Hematolojik Malignite Hastalarının Klinik Özellikleri ve Sonuçları
28. Clinical Characteristics and Outcomes of COVID-19 in Turkish Patients with Hematological Malignancies
29. Kazanılmış Faktör VIII ve IX İnhibitörü Olan Hastalarda İmmünosüpresif Tedavi Etkinlik ve Güvenilirliğinin Değerlendirilmesi.
30. The effect of CD34 count and clonogenic potential of hematopoietic stem cells on engraftment
31. Clinical Characteristics and Outcome of COVID-19 in Turkish Hematological Malignancy Patients
32. The Influence of ATG on the Outcomes of Patients With AML at the Time of Unrelated Donor Transplantation
33. The Efficacy of Therapeutic Thrombocytapheresis in Patients with Thrombocytosis
34. Duration of Objective Responses for Patients with Indolent Non-Hodgkin Lymphoma Discontinuing Treatment before Progression: Analysis from the Phase III Chronos-3 Trial Comparing Copanlisib Plus Rituximab with Placebo Plus Rituximab
35. The Efficacy and Safety of Low-Dose Inotuzumab Ozogamicin in Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia: Interim Results of a Phase 4 Study
36. Final Analysis of Keynote-170: Pembrolizumab in Relapsed or Refractory Primary Mediastinal Large B-Cell Lymphoma (PMBCL)
37. The Outcome of Autologous Hematopoietic Cell Transplantation in Elderly Patients with Aggressive Non-Hodgkin Lymphoma
38. Abstract CT001: CHRONOS-3: Randomized Phase III study of copanlisib plus rituximab vs rituximab/placebo in relapsed indolent non-Hodgkin lymphoma (iNHL)
39. Real-World Efficacy and Safety of Rituximab, Lenalidomide and İbrutinib Combination in Patients with Relapsed and/or Refractory Non-Hodgkin Lymphoma
40. Allogeneic Stem Cell Transplantation for Relapsed and/or Refractory Hodgkin Lymphoma: A Multicenter Real World Experience
41. Copanlisib + rituximab versus rituximab + placebo in patients with relapsed follicular (FL) or marginal zone lymphoma (MZL): Subset analysis from the phase III CHRONOS-3 trial.
42. ROBUST: A Phase III Study of Lenalidomide Plus R-CHOP Versus Placebo Plus R-CHOP in Previously Untreated Patients With ABC-Type Diffuse Large B-Cell Lymphoma
43. Highlighting the Prognostic Importance of Measurable Residual Disease Amongst Acute Myeloid Leukemia Risk Factors
44. Differences in liver pathology and clinical outcome between two patients with hepatitis B virus and graft verses host disease
45. Allojeneik Kök Hücre Naklinde Primer ve Sekonder Graft Yetmezliği
46. Pembrolizumab Monotherapy in Relapsed or Refractory Primary Mediastinal Large B-Cell Lymphoma (PMBCL): 3-Year Follow-up of the Keynote-170 Study
47. Miyelodisplastik Sendrom Hastalarının Akan Hücre Ölçer ile Yapılan Ogata Skorlaması Yoluyla Değerlendirilmesi: Pilot Çalışma
48. Allogeneic Stem Cell Transplantation in Myelodysplastic Syndrome
49. Safety and Outcome of Allogeneic Hematopoietic Stem Cell Transplantation in Mycosis Fungoides and Sezary Syndrome: A 7-year Tertiary Center Analysis
50. Our Treatment Approach to Hairy Cell Leukemia
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.